Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 20, 20 December 2023
Open
Access | Article
Application of different treatment methods for schizophrenia
* Author to whom correspondence should be addressed.
Abstract
Schizophrenia is a debilitating neurological and psychiatric disorder that can result in severe disability for those affected. The presence of this disorder can have far-reaching effects on all aspects of a person's life, affecting not only their personal and familial relationships, but also their social interactions, academic pursuits, and career prospects. Some individuals with schizophrenia may experience multiple cycles of symptom exacerbation and remission throughout their lifetime, with symptoms worsening and improving intermittently. However, for others, symptoms may progressively worsen over time and may even become increasingly severe, potentially persisting throughout their lifetime and significantly impacting their daily life and social relationships. As of today, most medications are still not perfect treatments for this disorder. And only a few, such as lumateperone, have shown initial success in improving and relieving patients' negative symptoms and cognitive dysfunction. In addition, psychological therapies are being developed, but therapists and psychiatrists are still limited in the number of treatments available. In the face of these unresolved challenges, different treatment methods have been conducted to evaluate investigational therapies, and new models are being constructed to study new pharmacological molecular therapeutic pathways. This research provides an overview of some of the current mainstream treatment strategies for schizophrenia and an outlook for the future.
Keywords
schizophrenia, treatments, mechanism
References
1. Lehman, A. F., Lieberman, J. A., Dixon, L. B., McGlashan, T. H., Miller, A. L., Perkins, D. O., Kreyenbuhl, J., American Psychiatric Association, & Steering Committee on Practice Guidelines (2004). Practice guideline for the treatment of patients with schizophrenia, second edition. The American journal of psychiatry, 161(2 Suppl), 1–56.
2. Marder, S. R. and Cannon, T. D., "Schizophrenia," The New England journal of medicine 381, 1753–1761 (2019).
3. Gu, X., Zheng, W., Guo, T., Ungvari, G. S., Chiu, H. F. K., Cao, X., D'Arcy, C., Meng, X., Ning, Y. and Xiang, Y., "Electroconvulsive Therapy for Agitation in Schizophrenia: Metaanalysis of Randomized Controlled Trials," Shanghai archives of psychiatry 29, 1–14 (2017).
4. Hooley J. M., "Expressed emotion and relapse of psychopathology," Annual review of clinical psychology 3, 329–352 (2007).
5. Fiszdon, J. M. and Reddy, L. F., "Review of social cognitive treatments for psychosis," Clinical psychology review 32, 724–740 (2012).
6. Kumar, B., Kuhad, A. and Kuhad, A., "Lumateperone: a new treatment approach for neuropsychiatric disorders," Drugs of today 54, 713–719 (2018).
7. Syed, A. B. and Brašić, J. R., "The role of lumateperone in the treatment of schizophrenia," Therapeutic advances in psychopharmacology 11, 20451253211034019 (2021).
8. Koblan, K. S., Kent, J., Hopkins, S. C., Krystal, J. H., Cheng, H., Goldman, R. and Loebel, A., "A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia," The New England journal of medicine 382, 1497–1506 (2020).
9. Lindemann, L., Meyer, C. A., Jeanneau, K., Bradaia, A., Ozmen, L., Bluethmann, H., Bettler, B., Wettstein, J. G., Borroni, E., Moreau, J. L. and Hoener, M. C., "Trace amine-associated receptor 1 modulates dopaminergic activity," The Journal of pharmacology and experimental therapeutics 324, 948–956 (2008).
10. Espinoza, S., Masri, B., Salahpour, A. and Gainetdinov, R. R., "BRET approaches to characterize dopamine and TAAR1 receptor pharmacology and signaling," Methods in molecular biology 964, 107–122 (2013).
11. Weeks, J. J., Grace, A. A. and Sved, A. F., "Nicotine Administration Normalizes Behavioral and Neurophysiological Perturbations in the MAM Rodent Model of Schizophrenia," The international journal of neuropsychopharmacology 24, 979–987 (2021).
12. Gomes, F. V. and Grace, A. A., "Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention," International journal of molecular sciences 22, 4467 (2021).
13. Perkins, D. O., Jeffries, C. D. and Do, K. Q., "Potential Roles of Redox Dysregulation in the Development of Schizophrenia," Biological psychiatry 88, 326–336 (2020).
14. Zhang, X. Y., Tan, Y. L., Cao, L. Y., Wu, G. Y., Xu, Q., Shen, Y. and Zhou, D. F., "Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics," Schizophrenia research 81, 291–300 (2006).
15. Upthegrove, R. and Khandaker, G. M., "Cytokines, Oxidative Stress and Cellular Markers of Inflammation in Schizophrenia," Current topics in behavioral neurosciences 44, 49–66(2020).
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
- ISBN (Print)
- 978-1-83558-213-8
- ISBN (Online)
- 978-1-83558-214-5
- Published Date
- 20 December 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/20/20230715
- Copyright
- 20 December 2023
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited